Novavax Company Profile (NASDAQ:NVAX)

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Novavax, Inc. (NASDAQ:NVAX) released its quarterly earnings data on Monday, May, 8th. The company reported ($0.16) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.18) by $0.02. The business had revenue of $5.68 million for the quarter, compared to the consensus estimate of $6.17 million. Novavax had a negative net margin of 1,466.36% and a negative return on equity of 787.38%. The company's revenue was up 34.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.29) earnings per share. View Novavax's Earnings History.

9 brokers have issued twelve-month target prices for Novavax's shares. Their forecasts range from $1.00 to $25.00. On average, they anticipate Novavax's stock price to reach $5.71 in the next year. View Analyst Ratings for Novavax.

Here are some recent quotes from research analysts about Novavax stock:

• 1. Cantor Fitzgerald analysts commented, "Important RSV vaccine data to be released next Monday. NVAX plans to host a conference call on Monday, July 24, at 4:30pm EDT, on which top-line data from the E-205 Phase 2 clinical trial of the RSV vaccine candidate in older adults will be discussed. The company’s press release notes that an update of the ongoing pivotal Prepare trial of the vaccine candidate in pregnant women will also be provided. Of the two programs, we believe the former is likely to be the greater value creator and, if the data are encouraging, could provide a catalyst for renewed investor interest in the stock." (7/21/2017)
• 2. According to Zacks Investment Research, "NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants. " (6/10/2017)
• 3. Chardan Capital analysts commented, "The company is at a pre-commercialization stage, although it does recognize revenue from research and development collaborations. Reported revenue in Q4 was $5.4M, which was inline with consensus." (2/28/2017)

Novavax saw a drop in short interest in June. As of June 30th, there was short interest totalling 56,851,825 shares, a drop of 11.6% from the June 15th total of 64,277,879 shares. Based on an average trading volume of 6,096,592 shares, the days-to-cover ratio is presently 9.3 days. Currently, 20.4% of the shares of the stock are sold short.

Some companies that are related to Novavax include TG Therapeutics (TGTX), Arena Pharmaceuticals (ARNA), Enanta Pharmaceuticals (ENTA), Crispr Theraptc (CRSP), Mesoblast Limited (MESO), Spectrum Pharmaceuticals (SPPI), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), ANI Pharmaceuticals (ANIP), Inovio Pharmaceuticals (INO), WAVE Life Sciences (WVE), ImmunoGen (IMGN), Agenus (AGEN), Cara Therapeutics (CARA), AC Immune SA (ACIU), Adamas Pharmaceuticals (ADMS), Abeona Therapeutics (ABEO) and PDL BioPharma (PDLI).

Novavax's management team includes the folowing people:

• James Francis Young Ph.D., Independent Chairman of the Board
• Stanley C. Erck, President, Chief Executive Officer, Director
• Barclay A. Phillips, Chief Financial Officer, Senior Vice President, Treasurer
• Gregory M. Glenn M.D., President, Research and Development
• John A. Herrmann III, Senior Vice President, General Counsel, Corporate Secretary
• John J. Trizzino, Senior Vice President - Commercial Operations
• James F. Cummings, Vice President - Clinical Development and Translational Medicine
• Rajiv I. Modi Ph.D., Director
• Gail Koziara Boudreaux, Independent Director
• Richard H. Douglas Ph.D., Independent Director

Novavax's stock is owned by many different of institutional and retail investors. Top institutional investors include Creative Planning (0.17%). Company insiders that own Novavax stock include Barclay A Phillips, Gail Boudreaux, Gary C Evans, Gregory M Glenn, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr and Stanley C Erck. View Institutional Ownership Trends for Novavax.

Novavax's stock was purchased by a variety of institutional investors in the last quarter, including Creative Planning. Company insiders that have bought Novavax stock in the last two years include Barclay A Phillips, Gail Boudreaux, Gregory M Glenn, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr and Stanley C Erck. View Insider Buying and Selling for Novavax.

Shares of Novavax can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Novavax stock can currently be purchased for approximately $1.48.